Telik News (NASDAQ:TELK)
| Latest Telik News Headlines | | Date | Time | Source | | | 07/22/2008 | 8:00AM | PRNUS | Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone
PALO ALTO, Calif., July 22 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced today that its library of diverse profiled compounds now exceeds 3.3 million. The expanded library significantly enhances Telik's patented drug discovery technology, Target Related Affinity Profiling (TRAP(R)). TRAP technology exploits... More...>> |
| 07/08/2008 | 8:00AM | PRNUS | Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
PALO ALTO, Calif., July 8 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK), today announced the publication of research in Bioorganic & Medicinal Chemistry Letters describing a novel class of small molecule compounds that could potentially lead to a new treatment for diabetes. These unique compounds are the result... More...>> |
| 06/10/2008 | 4:05PM | PRNUS | Telik Announces Patents on Compounds Related to TELINTRA
PALO ALTO, Calif., June 10 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK), announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA(R). Corresponding applications have already issued... More...>> |
| 06/05/2008 | 4:05PM | PRNUS | Telik Announces Presentation and Webcast at Needham Biotechnology Conference
PALO ALTO, Calif., June 5 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that company management will provide a corporate overview at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference in New York City on Wednesday, June 11, 2008 at 10:00 a.m. Eastern time (7:00 a.m... More...>> |
| 05/20/2008 | 4:05PM | PRNUS | Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
PALO ALTO, Calif., May 20 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK), today announced it has initiated two Phase 2 TELINTRA(R) studies -- one with TELINTRA tablets in myelodysplastic syndrome, or MDS, and a second with TELINTRA tablets in cancer patients at risk for chemotherapy-induced neutropenia, or CIN.
As... More...>> |
| 05/08/2008 | 4:05PM | PRNUS | Telik Announces First Quarter 2008 Financial Results
PALO ALTO, Calif., May 8 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) today reported a net loss of $9.8 million, or $0.19 per share, for the first quarter ended March 31, 2008, compared with a net loss of $16.3 million, or $0.31 per share, for the comparable period in 2007.
For the quarter ended March 31, 2008... More...>> |
| 05/01/2008 | 4:05PM | PRNUS | Telik Announces 2008 First Quarter Financial Release, Conference Call and Webcast
PALO ALTO, Calif., May 1 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that its 2008 first quarter conference call and webcast will be held on Thursday, May 8, 2008 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the first... More...>> |
| 04/17/2008 | 4:05PM | PRNUS | Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
PALO ALTO, Calif., April 17 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK), a biopharmaceutical company focused on discovering and developing drugs to treat serious diseases, today announced that it made four preclinical data presentations at the 99th Annual Meeting of the American Association for Cancer Research... More...>> |
| 04/07/2008 | 4:05PM | PRNUS | Telik Announces Preclinical Presentations at AACR Annual Meeting
PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.
Details of the presentations... More...>> |
| 02/27/2008 | 4:05PM | PRNUS | Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
PALO ALTO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) reported a net loss of $12.9 million, or $0.25 per share, for the fourth quarter ended December 31, 2007, compared with a net loss of $17.6 million, or $0.34 per share, for the comparable period in 2006.
For the quarter ended December 31... More...>> |
| 02/19/2008 | 8:15PM | PRNUS | Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
PALO ALTO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that its year-end conference call and webcast will be held on Wednesday, February 27, 2008 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the fourth... More...>> |
| 02/14/2008 | 4:05PM | PRNUS | Telik Announces Year-End Financial Release, Conference Call and Webcast
PALO ALTO, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that its year-end conference call and webcast will be held on Thursday, February 21, 2008 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the fourth... More...>> |
| 01/07/2008 | 4:05PM | PRNUS | Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
PALO ALTO, Calif., Jan. 7 /PRNewswire/ -- Telik, Inc. (NASDAQ:TELK) announced that company management will provide a corporate overview at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2008 at 7:30 a.m. Pacific time (10:30 a.m. Eastern time). A live and archived webcast... More...>> |
| 12/08/2007 | 5:30PM | PRNUS | Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
PALO ALTO, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced positive results from the multicenter Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets in myelodysplastic syndrome (MDS) that support the initiation of Phase 2 clinical trials. The data were reported at the 49th... More...>> |
| 12/03/2007 | 4:05PM | PRNUS | Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced it will report data from the Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets at the 49th annual meeting of the American Society of Hematology. The presentation is scheduled for Saturday, December 8, 2007, from... More...>> |
| 11/07/2007 | 4:05PM | PRNUS | Telik Announces Financial Results for 2007 Third Quarter
PALO ALTO, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) reported a net loss of $11.6 million, or $0.22 per share, for the third quarter ended September 30, 2007, compared with a net loss of $20.5 million, or $0.39 per share, for the comparable period in 2006.
For the quarter ended September 30... More...>> |
| 11/01/2007 | 4:05PM | PRNUS | Telik Announces 2007 Third Quarter Financial Release, Conference Call and Webcast
PALO ALTO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that its 2007 third quarter conference call and webcast will be held on Wednesday, November 7, 2007 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for... More...>> |
| 10/25/2007 | 4:30PM | PRNUS | Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
PALO ALTO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) reported positive preclinical data from its ongoing program to develop novel small molecule inhibitors of validated cancer targets including aurora kinases and VEGFR2. The data were presented today at the AACR-NCI-EORTC Conference on Molecular... More...>> |
| 10/18/2007 | 4:05PM | PRNUS | Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that preclinical data from its program to develop novel small molecule kinase inhibitors will be presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The presentation, "In Vitro... More...>> |
| 10/15/2007 | 7:30AM | PRNUS | FDA Removes Partial Hold on TELCYTA Clinical Development
PALO ALTO, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that the U.S. Food and Drug Administration (FDA) has removed the partial hold on TELCYTA(R) (canfosfamide HCl, TLK286) clinical trials. This action follows a complete review of TELCYTA data by the agency and permits the resumption... More...>> |
|
|
|